C23H30N4O6.C2HF3O2
Neat
458.52 114.02
1950635-16-1; E3 ligase Ligand-Linker Conjugates 17; Thalidomide-O-amido-C8-NH2 (TFA); N-(8-aminooctyl)-2-((2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindolin-4-yl)oxy)acetamide 2, 2, 2-trifluoroacetate; MFCD31560485; N-(8-aminooctyl)-2-[2-(2, 6-dioxo-3-piperidyl)-1, 3-dioxo-isoindolin-4-yl]oxy-acetamide;2, 2, 2-trifluoroacetic acid; N-(8-aminooctyl)-2-[2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-4-yl]oxyacetamide;2, 2, 2-trifluoroacetic acid; Thalidomide-O-amido-C8-NH2 TFA; orb573255; SCHEMBL17839806; C25H31F3N4O8; EX-A3885; AKOS037653313; AT18336; CS-7756; Thalidomide-O-amido-C8-amine TFA salt; Thalidomide-O-amido-C8-NH2 and TFA salt; E3 ligase Ligand-Linker Conjugates 17?; AC-37744; DA-72966
N-(8-aminooctyl)-2-[2-(2, 6-dioxopiperidin-3-yl)-1, 3-dioxoisoindol-4-yl]oxyacetamide;2, 2 and 2-trifluoroacetic acid
InChI=1S/C23H30N4O6.C2HF3O2/c24-12-5-3-1-2-4-6-13-25-19(29)14-33-17-9-7-8-15-20(17)23(32)27(22(15)31)16-10-11-18(28)26-21(16)30;3-2(4,5)1(6)7/h7-9,16H,1-6,10-14,24H2,(H,25,29)(H,26,28,30);(H,6,7)